Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group
Korean Journal of Pathology
;
: 100-106, 2013.
Article
in English
| WPRIM
| ID: wpr-56554
ABSTRACT
Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quinazolines
/
Protein-Tyrosine Kinases
/
Patient Selection
/
ErbB Receptors
/
Erlotinib Hydrochloride
/
Korea
/
Lung
/
Lung Neoplasms
Type of study:
Practice guideline
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Korean Journal of Pathology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS